DARZALEX FASPRO^® monotherapy is the first and only FDA-approved treatment in high-risk smoldering multiple myeloma¹DARZALEX FASPRO^® monotherapy is now approved in high-risk smoldering multiple myeloma¹

Frontline DARZALEX^®- and DARZALEX FASPRO^®–Based Regimens Are Foundational
in Multiple Myeloma Treatment Approaches^1,2

Explore a
Triplet
Regimen with DARZALEX^®
(daratumumab)

MAIA: DRd in Transplant-Ineligible NDMM Exploratory Subgroup Analyses

Discover a
Quad
Regimen with DARZALEX FASPRO^®
(daratumumab and hyaluronidase-fihj)

CEPHEUS: DVRd in Transplant-
Ineligible NDMM PERSEUS: DVRd in Transplant-
Eligible NDMM

MAIA: Post hoc
analyses of
Treatment Duration
with DARZALEX^®+ Rd

See Post Hoc Analyses

References:

DARZALEX^® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
DARZALEX FASPRO^® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.